Dr. Umar

Overview Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, neurofibrillary tangles, neuroinflammation, and metabolic dysfunction, ultimately leading to cognitive decline and dementia. Emerging research highlights the microbiota-gut-brain axis as a crucial factor in AD pathogenesis, with gut dysbiosis contributing to neuroinflammation, immune dysregulation, and blood-brain barrier permeability. Microbial metabolites, such […]

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by social, communication, and behavioral challenges. It involves genetic and environmental factors, including microbiome imbalances which influence symptom severity and overall health.

Traditionally linked to genetic predispositions and environmental exposures, emerging evidence highlights the microbiome as a critical and underappreciated factor influencing breast cancer progression, immune response, and treatment outcomes.

Type 1 diabetes is an autoimmune condition in which pancreatic β-cells are destroyed, causing insulin deficiency and hyperglycemia. It typically arises in youth and requires lifelong insulin therapy. This article provides a clinician-focused review of T1D’s causes, mechanisms, complications, diagnosis, and management, including emerging multi-omics insights.

Gut microbiota signatures in pediatric type 1 diabetes include lower Firmicutes/Actinobacteria, higher Bacteroidetes, and reduced Firmicutes:Bacteroidetes ratio, with depleted Bifidobacterium/Lactobacillus and increased Clostridium linked to worse glycemia.

New-onset pediatric T1D in Sonoran Mexico is associated with a genus-level shift toward Bacteroides enrichment and Prevotella depletion, while insulin-treated cases show intermediate, heterogeneous profiles. Diversity differences were mainly compositional (beta diversity), supporting a stage-sensitive microbiome signature rather than broad phylum changes.

This U.S. cross-sectional study links gut microbiome in type 1 diabetes risk with specific taxon shifts rather than reduced diversity, highlighting Catenibacterium/Prevotellaceae/RC9-gut-group increases in seropositivity and Lactobacillus/Staphylococcus depletion in at-risk and new-onset states.

Newly diagnosed Chinese children with T1DM showed t1dm-gut-microbiota-signatures marked by lower richness and specific taxonomic shifts, notably higher Blautia and lower Haemophilus/Lachnospira/Dialister/Intestinimonas. Blautia correlated with HbA1c and autoantibody measures, linking microbiota patterns to metabolic and autoimmune activity.

This pediatric case-control study found a distinct type-1-diabetes-gut-microbiota signature versus MODY2 and healthy controls, featuring higher Bacteroides/Veillonella and lower Faecalibacterium/Roseburia, alongside increased LPS, cytokines, and zonulin and immune-related functional pathway enrichment.

This pilot study profiled gut fungi in adults with T1D, T2D, and controls. Basidiomycota and Malassezia predominated, but T1D showed striking Saccharomyces depletion and lipid-linked correlations, while T2D showed cholesterol-linked Malassezia signals.

Plasma metabolomics distinguished type 1 diabetes stages. New-onset disease showed higher gut bacteria–linked 3-phenylpropionic acid and lower hypotaurine, while later-stage disease showed higher 5-methylcytosine. Ratios of phenylalanine to 3-PPA improved stage classification.

In hepcidin in pediatric type 1 diabetes, single serum hepcidin did not distinguish functional iron deficiency from normal iron status, though it was markedly low in absolute iron deficiency. The study provides iron-phenotype labeling guidance but contains no microbiome taxa or metabolite data.

This review explains how ZnT8 autoantibodies refine type 1 diabetes prediction and classification, emphasizing late-appearing epitope spreading, genotype-shaped epitope specificity, and rapid post-diagnosis decline. It also flags a candidate microbial mimicry link with Mycobacterium avium subsp. paratuberculosis.

Multi-omics profiling shows new-onset pediatric T1D features reduced butyrate and bile-acid metabolism capacity with increased LPS potential; these shifts associate with worse glycemia and inflammatory signaling and can transfer dysglycemia via FMT in mice, while butyrate is protective and LPS is harmful.

Global-childhood-type-1-diabetes-epidemiology shows rising childhood T1D incidence/prevalence but falling DALYs and mortality from 1990–2021. High-income regions carry the most cases, while Sub-Saharan Africa carries the most harm, and mortality inequality has worsened.

Lipocalin-2 (LCN2/NGAL) is an inflammation-responsive protein central to microbiome–host interactions. It limits bacterial growth by binding iron-scavenging siderophores and is measurable in stool as a noninvasive marker of intestinal inflammation, including IBD.

Serum LCN2 is a sensitive blood biomarker of active ulcerative colitis, mechanistically driven by IL-17A/IL-22/TNF-α synergy in epithelial cells. In Crohn’s disease, IL23R risk alleles associate with lower LCN2, implying genetically constrained antimicrobial responses.

This study shows fecal NGAL is a stable, high-performing stool biomarker for active IBD, comparable to fecal calprotectin, with added biological value because NGAL reflects epithelial as well as neutrophil inflammation.

This mouse study validates fecal lipocalin 2 biomarker as a highly sensitive, non-invasive stool marker that detects low-grade and severe colitis, rises within 1 day of injury, tracks spontaneous IL-10–mediated colitis severity, and declines with mucosal healing.

This study shows that IL-17/IL-22-driven lipocalin-2 shapes inflamed gut ecology by blocking enterochelin-mediated iron uptake, selecting for lipocalin-2–resistant S. Typhimurium with salmochelin (iroBCDE iroN/iroN). Lipocalin-2 thus acts as an inflammatory ecological filter.

24p3/Ngal is shown to bind iron and deliver it into renal cells via receptor-mediated uptake and acidic endosomal trafficking, regulating iron-responsive genes. In embryonic kidney, 24p3 and transferrin target different developmental cell populations, supporting stage-specific iron delivery mechanisms.

Lipocalin 2 sequestrates bacterial siderophores, restricting iron uptake by enterobactin-dependent Enterobacteriaceae. In mice, lipocalin 2 deficiency causes higher E. coli bacteremia and mortality, while bypass siderophores (ferrichrome) overcome protection and S. aureus remains unaffected.

Terpenes and terpenoids are plant isoprenoids that can shape gut microbial ecology and intestinal barrier function. Microbiome studies of limonene, carvacrol, and menthol suggest clinically relevant, compound-specific effects that support emerging microbiome-informed nutrition and therapeutics.

A menthol/limonene/gingerol supplement added to standard care improved IBS/IBS+FD symptoms over 30 days versus placebo, without clear FDR-significant microbiome shifts. Fusobacterium (low abundance) showed the strongest positive correlation with symptom severity, highlighting a potential severity-associated microbiome marker.